JP2022517618A5 - - Google Patents

Info

Publication number
JP2022517618A5
JP2022517618A5 JP2021541017A JP2021541017A JP2022517618A5 JP 2022517618 A5 JP2022517618 A5 JP 2022517618A5 JP 2021541017 A JP2021541017 A JP 2021541017A JP 2021541017 A JP2021541017 A JP 2021541017A JP 2022517618 A5 JP2022517618 A5 JP 2022517618A5
Authority
JP
Japan
Prior art keywords
cells
cell
hematopoietic stem
genetically modified
progenitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021541017A
Other languages
English (en)
Japanese (ja)
Other versions
JP7784707B2 (ja
JP2022517618A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/013887 external-priority patent/WO2020150478A1/en
Publication of JP2022517618A publication Critical patent/JP2022517618A/ja
Publication of JP2022517618A5 publication Critical patent/JP2022517618A5/ja
Priority to JP2025202676A priority Critical patent/JP2026035683A/ja
Application granted granted Critical
Publication of JP7784707B2 publication Critical patent/JP7784707B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021541017A 2019-01-16 2020-01-16 系統特異的抗原の阻害のための組成物および方法 Active JP7784707B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025202676A JP2026035683A (ja) 2019-01-16 2025-11-25 系統特異的抗原の阻害のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962793210P 2019-01-16 2019-01-16
US62/793,210 2019-01-16
US201962852573P 2019-05-24 2019-05-24
US62/852,573 2019-05-24
PCT/US2020/013887 WO2020150478A1 (en) 2019-01-16 2020-01-16 Compositions and methods for inhibition of lineage specific antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025202676A Division JP2026035683A (ja) 2019-01-16 2025-11-25 系統特異的抗原の阻害のための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022517618A JP2022517618A (ja) 2022-03-09
JP2022517618A5 true JP2022517618A5 (cg-RX-API-DMAC7.html) 2023-01-25
JP7784707B2 JP7784707B2 (ja) 2025-12-12

Family

ID=71613437

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021541017A Active JP7784707B2 (ja) 2019-01-16 2020-01-16 系統特異的抗原の阻害のための組成物および方法
JP2025202676A Pending JP2026035683A (ja) 2019-01-16 2025-11-25 系統特異的抗原の阻害のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025202676A Pending JP2026035683A (ja) 2019-01-16 2025-11-25 系統特異的抗原の阻害のための組成物および方法

Country Status (12)

Country Link
US (1) US20210260130A1 (cg-RX-API-DMAC7.html)
EP (1) EP3911338A4 (cg-RX-API-DMAC7.html)
JP (2) JP7784707B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210129048A (cg-RX-API-DMAC7.html)
CN (1) CN113474452A (cg-RX-API-DMAC7.html)
AU (1) AU2020209218A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021014010A2 (cg-RX-API-DMAC7.html)
CA (1) CA3126677A1 (cg-RX-API-DMAC7.html)
IL (1) IL284853A (cg-RX-API-DMAC7.html)
MX (1) MX2021008490A (cg-RX-API-DMAC7.html)
SG (1) SG11202107639UA (cg-RX-API-DMAC7.html)
WO (1) WO2020150478A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102709603B1 (ko) 2017-02-28 2024-09-27 보르 바이오파마 인크. 계통 특이적 단백질의 억제를 위한 조성물 및 방법
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
AU2020280103A1 (en) * 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
AU2020338011A1 (en) * 2019-08-28 2022-03-10 Vor Biopharma Inc. Compositions and methods for CLL1 modification
EP4204565A1 (en) * 2020-08-28 2023-07-05 Vor Biopharma Inc. Compositions and methods for cll1 modification
CA3199623A1 (en) * 2020-10-27 2022-05-05 Vor Biopharma Inc. Compositions and methods for treating hematopoietic malignancy
CN116600821A (zh) * 2020-10-27 2023-08-15 Vor生物制药股份有限公司 用于治疗造血系统恶性肿瘤的组合物和方法
CN115443333B (zh) * 2021-04-27 2025-04-25 上海驯鹿生物技术有限公司 一种基因编辑的造血干细胞及其与car-t细胞的联合应用
WO2023283585A2 (en) 2021-07-06 2023-01-12 Vor Biopharma Inc. Inhibitor oligonucleotides and methods of use thereof
EP4381062A1 (en) 2021-08-02 2024-06-12 Vor Biopharma Inc. Compositions and methods for gene modification
WO2024015925A2 (en) 2022-07-13 2024-01-18 Vor Biopharma Inc. Compositions and methods for artificial protospacer adjacent motif (pam) generation
WO2024073751A1 (en) 2022-09-29 2024-04-04 Vor Biopharma Inc. Methods and compositions for gene modification and enrichment
WO2025030010A1 (en) 2023-08-01 2025-02-06 Vor Biopharma Inc. Compositions comprising genetically engineered hematopoietic stem cells and methods of use thereof
BG113932A (bg) * 2024-07-19 2026-01-30 Медицински университет – Пловдив Панели и китове от реагенти за измерване на минимална резидуална болест при детска в-клетъчна прекурсорна остра лимфобластна левкемия чрез имунофенотипизация

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2765710T3 (es) * 2014-04-03 2020-06-10 Cellectis Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer
AU2016251687C1 (en) * 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CA2986310A1 (en) * 2015-05-11 2016-11-17 Editas Medicine, Inc. Optimized crispr/cas9 systems and methods for gene editing in stem cells
IL258491B2 (en) * 2015-10-16 2023-09-01 Univ Columbia Preparations and methods for inhibiting antigens of a particular lineage
CA3009308A1 (en) * 2015-12-23 2017-06-29 Chad Albert COWAN Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
AU2018224387B2 (en) * 2017-02-22 2024-08-08 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3676372A4 (en) * 2017-08-28 2021-06-02 The Trustees of Columbia University in the City of New York CD33 EXON 2 DEFICIENT DONOR STEM CELLS FOR USE WITH AGENTS AGAINST CD33

Similar Documents

Publication Publication Date Title
JP7168641B2 (ja) 刺激性骨髄系細胞及び非刺激性骨髄系細胞の調節
Li et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity
JP2023528415A5 (cg-RX-API-DMAC7.html)
JP7411578B2 (ja) 癌を治療するための物質及び方法
JP7471289B2 (ja) 抗liv1免疫細胞癌療法
JP2022516389A (ja) 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーT(iNKT)細胞
CA3022611A1 (en) Genetically engineered cells and methods of making the same
JP2018531260A5 (cg-RX-API-DMAC7.html)
EP3873205B1 (en) Materials and methods for treating cancer
JP2022517618A (ja) 系統特異的抗原の阻害のための組成物および方法
EP4238990A1 (en) Fully human antibody targeting cd5, and fully human chimeric antigen receptor (car) and application thereof
EP4476267A2 (en) Chimeric antigen receptors binding steap1
US20230233677A1 (en) Compositions and methods for enhancing immune response
KR20240145485A (ko) 세포-표면 수용체의 에피토프 조작
WO2022133042A1 (en) Cea5 binding molecules and uses thereof
US20240158467A1 (en) Materials and methods for treating cancer
Caforio et al. AATF/Che-1 RNA polymerase II binding protein overexpression reduces the anti-tumor NK-cell cytotoxicity through activating receptors modulation
CN114057871A (zh) 抗人periostin单克隆嵌合抗体及应用
US20240325537A1 (en) Cellular therapies for cancer by inhibition of monocarboxylate transporter 11
WO2025231213A2 (en) Modified b cells and methods for use thereof
US20250249096A1 (en) Compositions and Methods for Immunotherapy
Pedrazzani MOBILIZATION-BASED CHEMOTHERAPY-FREE ENGRAFTMENT OF GENE EDITED HEMATOPOIETIC STEM CELLS
WO2024151213A2 (en) Blockade of cd8 expression and chimeric antigen receptors for immunotherapy of t-cell and nk-cell malignancies
WO2026058265A1 (en) Compounds and methods for preparing engineered lymphocytes
WO2026016998A1 (zh) 编码针对GPC3和CD3双特异性抗体的mRNA分子